Table 5.
Quality, measured in %, of the included AMD clinical guidelines, based on the six assessment domains of the Appraisal of Guidelines for Research and Evaluation II (AGREE II) appraisal tool. The scores for each of the six domains were calculated by summing up all the scores of the individual items for that domain, and then scaling the total as a percentage of the maximum possible score for each domain.
| Clinical Guideline | AGREE II Domains (%) | |||||
|---|---|---|---|---|---|---|
| Scope and Purpose |
Stakeholder Involvement |
Rigour of Development |
Clarity of Presentation |
Applicability | Editorial Independence |
|
| American Optical Association 2004 | 52.8 | 30.6 | 9.2 | 30.6 | 10.9 | 87.5 |
| International Council of Ophthalmology 2007 | 58.3 | 30.6 | 10.2 | 58.3 | 2.2 | 0.0 |
| Spanish Retina and Vitreous Society 2009 | 63.9 | 41.7 | 21.4 | 36.1 | 13.0 | 0.0 |
| Canadian Expert Consensus 2012 | 75.0 | 47.2 | 36.7 | 75.0 | 28.3 | 20.8 |
| German Ophthalmological Society 2014 | 30.6 | 25.0 | 19.4 | 52.8 | 0.0 | 0.0 |
| Eye Health Council of Ontario (Canada) 2015 | 61.1 | 22.2 | 14.3 | 41.7 | 13.0 | 20.8 |
| National Health Committee (New Zealand) 2015 | 75.0 | 13.9 | 20.4 | 55.6 | 30.4 | 0.0 |
| American Academy of Ophthalmology 2015 | 83.3 | 63.9 | 72.4 | 94.4 | 17.4 | 75.0 |
| Vitreo-Retina Society of the Philippines 2016 | 83.3 | 44.4 | 56.1 | 88.9 | 13.0 | 45.8 |
| NICE Clinical Knowledge Summary (CKS) 2016 | 88.9 | 83.3 | 68.4 | 91.7 | 39.1 | 87.5 |
| Clinical Advisory Committee (United States) 2017 | 52.8 | 22.2 | 9.2 | 44.4 | 4.3 | 0.0 |
| NICE Guideline (NG82) 2018 | 94.4 | 88.9 | 95.9 | 100.0 | 97.8 | 100.0 |
| Optometry Australia 2019 | 83.3 | 41.7 | 19.4 | 75.0 | 19.6 | 0.0 |
| Median (range) | 75.0 (range 30.6 to 94.4%) |
41.7 (range 13.9 to 88.9%) |
20.4 (range 9.2 to 95.9) |
58.3 (range 30.6 to 100%) |
13.0 (range 2.2 to 97.8%) |
20.8 (range 0 to 100%) |